C. Peedell

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Nicholas D. James, Matthew R. Sydes, Noel W. Clarke et al. · The Lancet · 2015 · 2K citations · Full text

Medicine, Oncology, Urology +17

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

Matthew R. Sydes, Melissa Spears, Malcolm D. Mason et al. · Annals of Oncology · 2018 · 250 citations · Full text

Medicine, Oncology, Urology +17

SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status

J. Maguire, Iftekhar Khan, R. McMenemin et al. · European Journal of Cancer · 2014 · 131 citations

Medicine, Oncology, Radiation Oncology +16

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Gerhardt Attard, Laura Murphy, Noel W. Clarke et al. · The Lancet Oncology · 2023 · 102 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Reduced Fractionation in Lung Cancer Patients Treated with Curative-intent Radiotherapy during the COVID-19 Pandemic

Corinne Faivre‐Finn, John D. Fenwick, K. Franks et al. · Clinical Oncology · 2020 · 63 citations · Full text

Medicine, Oncology, Radiation Oncology +17